The third generation oral contraceptive controversy

Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.

Four epidemiologic studies showed a twofold increase in risk of deep venous thrombosis with the use of oral contraceptives containing third-generation progestins, relative to second-generation products. These findings have been strongly debated ever since, and new studies have been added. In the current article we examine whether the findings can be explained by potential biases or other shortc...

End of the line for "third-generation-pill" controversy?

Through modification of an in vitro test for thrombosis formation, a Dutch research group has made three significant findings: 1) third-generation oral contraceptives (OCs) induce a resistance to the blood's natural anticoagulation system of a magnitude close to that induced by a mutation in coagulation factor V Leiden; 2) second-generation OCs show only part of the effect; and 3) in OC users h...

Third generation oral contraceptives and vascular risks.

Third generation oral contraceptives (OC), containing the progestins desogestrel and gestodene, were introduced in the 1980s in a attempt to lower the risk of cardiovascular side effects. However, the observation that desogestrel and gestodene in combined OC were related to a 50 to 100% greater risk of venous thromboembolism (VTE) suggested that the issue is more complex than originally thought...

Third generation cephalosporins in the parenteral to oral switch.

In the present economic climate, it is increasingly necessary to ensure the cost-effectiveness of all aspects of healthcare. The expenditure on medications in a hospital is largely determined by the workload and throughput, but efforts to rationalise the use of medications will result in benefits both in patient care and overall costs. The purpose of this report is to discuss the advantages o...

Taking a lesson from England: the contraceptive controversy.